medcelerator · clinician one-pager
Once-Daily Switch Pill for Adults with Suppressed HIV
Idvynso (doravirine/islatravir) for HIV-1 — switch-only dual tablet
Health Canada/FDA Approved · United States, Canada · September 4, 2026
Condition: HIV
Who this is for
Idvynso (doravirine and islatravir) is a daily pill for adults whose HIV (human immunodeficiency virus) is already under control. Canada and the United States approved it for switching, not for starting treatment.
Next clinical step
Health Canada and the US Food and Drug Administration (FDA) have approved this medicine. In Canada and the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed. In Canada, it is authorised but may not be on sale yet.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216964Orig1s000lbl.pdf
Possible routes (not confirmed)
Canada · Prescription · Applicability unknown
Canada prescription (Health Canada NOC, DIN 02568748)
Health Canada issued a Notice of Compliance (NOC) on 2026-06-03 (DIN 02568748), but the Drug Product Database does not list it as marketed yet; Canadian supply date not confirmed.
https://health-products.canada.ca/api/drug/drugproduct/?din=02568748
General resources for further research
Canadian Clinical Trial Search Portal (Health Canada)
Health Canada's public search of the drug and biologic clinical trials it has authorised in Canada (phase 1 to 3, since April 2013). Search by condition, drug, or trial status and see where trials are running. It replaced the Health Canada Clinical Trials Database in July 2026. A listing is not enrolment, and Health Canada does not recruit patients: ask your clinician and contact the trial sponsor.
https://clinical-trials-search.canada.ca/en/home
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/idvynso-doravirine-islatravir